Aeterna Zentaris, Inc. (USA) (NASDAQ:AEZS)

CAPS Rating: 4 out of 5

A growing global biopharmaceutical company focused on endrocrine therapy and oncology, in drug discovery, development and commercialization.

Recs

0
Player Avatar K3VIN0 (< 20) Submitted: 1/8/2012 4:56:09 AM : Outperform Start Price: $1.66 AEZS Score: -73.72

Perifosine is looking good. Pipeline shows potential.

Featured Broker Partners


Advertisement